29 results on '"Pharmaceutical industry -- Product development -- Economic aspects"'
Search Results
2. Considering Bio/Pharma Reformulation Strategies: Reformulation strategies are useful tools for more than just stretching out the potential return on investment for a product
3. IN DEFENSE OF COVID BILLIONAIRES
4. New Clinical Trials and Studies Findings from University of Alberta Discussed (The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials)
5. Nicox to Receive 15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial from Ocumension Therapeutics under Amended Agreement
6. 4 Ways to fix the clinical trial: clinical trials are crumbling under modern economic and scientific pressures. Nature looks at ways they might be saved
7. Restructurally sound: facing dwindling product pipelines and looming patent cliffs, nearly all of the world's major drugmakers have recently overhauled their research and development activities. Brendan Borrell asks what difference these efforts have made
8. Safety versus speed in drug development: the heightened focus on risk raises concerns about delays in approving new drugs
9. Stop costly Phase III failures: more efficient drug development through modeling and simulations can save sponsors time and money
10. The Suffocation of Innovation: When the Left fights progress, fight back
11. Samsung Bioepis to develop lower-cost copy of Roche eye drug Lucentis
12. Samsung Bioepis to develop lower-cost copy of Roche eye drug Lucentis
13. The dilemma with orphan drugs: orphan drugs for rare diseases are a major area of investment for pharmaceutical companies but are they becoming too expensive for Europe to afford them?
14. Reducing the number of failures in early stage development: Phase 0 studies, though not widely accepted, could effectively bridge the gap between preclinical and Phase I studies, and reduce the number of drug failures owing to differences in drug behaviour between animals and humans
15. The R&D hurdles for neglected diseases: modern medicines have dramatically improved the health of millions of people worldwide, but the healthcare situation in industrialized countries is a stark contrast to that in the least developed countries where neglected diseases are still prevalent
16. Analysis of drug failures underscores value of robust phase 2 testing
17. Nonprofit disease groups earmark grants for drug repositioning
18. Companies ponder how truly 'personal' medicines can get
19. Picking the blockbusters of tomorrow: choosing the right drug candidate is key for custom manufacturers. A look at potential winners in the near term
20. Pharma report shows strength of drug-development in Indiana: clinical trials are delivering a double dose of good news for Hoosiers, benefitting both patients and the state economy
21. Business watch
22. Cellegy sells Australian unit
23. Drug discovery
24. Innovative Medicines Initiative unfair to academia
25. Four years later
26. India and China attracting R&D spend from the West
27. Geese of a different feather. (Soundings)
28. When Medivation gained clearance in March to start its phase III trial of MDV3100 in prostate cancer, a company executive said the firm would consider partnering the drug if the right opportunity came along--as it had for Alzheimer's disease drug Dimebon, which scored a potential $725-million deal with Pfizer last year
29. Poniard Pharmaceuticals
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.